Insider Insights
03.03.2022
Ensuring patients have access to orphan drugs

According to the pharmaceutical industry association, Farmaindustria, 40% of orphan drugs approved i...

Read more
Insider Insights
03.03.2022
NICE recommends routine use of Zejula

The National Institute for Health and Care Excellence (NICE) has recommended GlaxoSmithKline’s Zej...

Read more
Insider Insights
01.03.2022
Spotlight on access to orphan drugs

The Ministry of Health hhas published a report on the “evolution of funding and fixing of the pric...

Read more
Insider Insights
16.02.2022
AIFA announces reimbursement of oral SMA treatment

The Italian Medicines Agency (AIFA) has announced that Roche’s Evyrsdi (risdiplam) is reimbursed w...

Read more
Insider Insights
07.02.2022
NHS England announces access deal for Libmeldy

The news comes after the health service negotiated a “significant confidential discount” to the ...

Read more
News
24.11.2021
PMA Insights: Week 47 2021

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
Articles
22.11.2021
NICE cost effective medicines

When making a decision about the approval of a new product NICE (National Institute for Health and C...

Read more
Articles
27.09.2021
Access for rare disease treatments

Innovative therapies for rare diseases may only be available in a select number of countries in Euro...

Read more
News
04.08.2021
PMA Insights: Week 31 2021

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
Articles
26.07.2021
New Innovative Medicines Fund

NHS England, the UK’s publicly funded healthcare system, will be introducing a £340m fund dedicat...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.